https://www.tempus.com/publications/uncovering-genomic-differences-between-small-and-large-cell-extra-pulmonary-neuroendocrine-carcinomas/ 2025-01-09T20:05:20+00:00 https://www.tempus.com/publications/molecular-landscape-of-extra-pulmonary-small-cell-neuroendocrine-carcinomas-based-on-site-of-origin/ 2025-01-09T20:07:00+00:00 https://www.tempus.com/publications/comparison-of-pulmonary-versus-extra-pulmonary-small-cell-neuroendocrine-carcinomas-demonstrate-distinct-genomic-alterations/ 2025-01-09T20:07:16+00:00 https://www.tempus.com/news/pr/tempus-announces-its-first-ever-whole-genome-sequencing-assay-xh/ 2025-01-13T13:30:57+00:00 https://www.tempus.com/publications/efficient-and-generalizable-prediction-of-molecular-alterations-in-multiple-cancer-cohorts-using-he-whole-slide-images/ 2025-01-10T22:49:20+00:00 https://www.tempus.com/news/tempus-announces-preliminary-fourth-quarter-and-full-year-2024-results/ 2025-01-13T13:00:32+00:00 https://www.tempus.com/news/pr/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test/ 2025-01-15T13:30:56+00:00 https://www.tempus.com/resources/content/blog/expanding-the-boundaries-of-precision-medicine-and-research-with-tempus-one/ 2025-01-14T20:28:43+00:00 https://www.tempus.com/wp-content/uploads/2025/01/One-@-JPM-thumbnail-1.jpg https://www.tempus.com/news/tempus-one-introduces-new-genai-capabilities-to-query-millions-of-unstructured-documents-for-research-and-clinical-care/ 2025-01-14T23:01:07+00:00 https://www.tempus.com/news/pr/tempus-announces-national-launch-of-olivia-its-ai-enabled-personal-health-concierge-app-for-patients/ 2025-01-21T13:30:51+00:00 https://www.tempus.com/resources/content/articles/qa-harnessing-ai-with-multimodal-data-to-transform-drug-development/ 2025-01-23T19:27:42+00:00 https://www.tempus.com/wp-content/uploads/2024/11/QA_-Harnessing-AI-with-multimodal-data-to-transform-drug-development.png https://www.tempus.com/wp-content/uploads/2024/11/2024-11_QA-Article-Chart-1.png https://www.tempus.com/resources/content/case-studies/harnessing-ai-and-time-to-increase-clinical-trial-enrollment/ 2025-01-23T19:30:02+00:00 https://www.tempus.com/wp-content/uploads/2024/10/Case-Study_Cleveland-Clinic.jpg https://www.tempus.com/publications/hypofractionated-radiation-therapy-for-subcutaneous-rosai-dorfman-disease-a-case-report/ 2025-01-23T21:49:18+00:00 https://www.tempus.com/publications/molecular-differences-in-pancreatic-ductal-adenocarcinomas-from-black-versus-white-patients/ 2025-01-23T22:00:30+00:00 https://www.tempus.com/publications/liberty-liquid-biopsy-for-relapsed-refractory-neuroblastoma-a-pilot-study-of-characterization-of-circulating-tumor-dna-alterations-in-patients-with-relapsed-and-refractory-neuroblastoma-usi/ 2025-01-23T22:43:38+00:00 https://www.tempus.com/publications/characterization-of-the-tumor-immune-microenvironment-time-and-somatic-landscape-in-gastrointestinal-gi-malignancies-with-mtap-deletions-del/ 2025-01-27T19:12:06+00:00 https://www.tempus.com/publications/concordance-between-human-epidermal-growth-factor-receptor-2-her2-status-by-immunohistochemistry-ihc-and-next-generation-sequencing-ngs-in-tissue-and-blood-samples-from-gastric-and-gastroesophag/ 2025-01-27T19:24:00+00:00 https://www.tempus.com/publications/association-between-ex-vivo-pharmacotyping-of-patient-derived-tumor-organoids-and-personalized-therapeutic-options-for-patients-with-biliary-tract-cancer/ 2025-01-27T19:24:41+00:00 https://www.tempus.com/publications/molecular-characteristics-of-early-onset-versus-average-onset-gastroesophageal-adenocarcinoma/ 2025-01-27T19:25:29+00:00 https://www.tempus.com/resources/content/case-studies/addressing-health-disparities-at-a-large-academic-medical-center-ai-driven-cardiac-care-for-aortic-stenosis-and-mitral-regurgitation/ 2025-01-27T23:22:08+00:00 https://www.tempus.com/wp-content/uploads/2025/01/Case-Study_Addressing-health-disparities-at-a-large-academic-medical-center.jpg https://www.tempus.com/publications/geospatial-and-molecular-characterization-of-tumor-immune-cell-infiltration-in-nsclc/ 2025-01-29T22:49:11+00:00 https://www.tempus.com/publications/evaluating-biomarkers-of-immunotherapy-response-in-a-real-world-metastatic-nsclc-cohort/ 2025-01-31T21:00:23+00:00 https://www.tempus.com/publications/a-phase-ii-randomized-double-blind-study-of-the-use-of-rucaparib-versus-placebo-maintenance-therapy-in-metastatic-and-recurrent-endometrial-cancer/ 2025-01-31T21:20:50+00:00 https://www.tempus.com/publications/real-world-clinical-genomics-study-of-hr-her2-metastatic-breast-cancers-treated-by-cdk4-6i-plus-endocrine-therapies-revealed-a-drug-resistant-tumor-segment-characterized-by-er-independence-2/ 2025-01-31T21:34:01+00:00 https://www.tempus.com/publications/pparg-amplification-is-associated-with-lack-of-response-to-anti-pd1-in-muscle-invasive-urothelial-cancer/ 2025-01-31T22:10:39+00:00 https://www.tempus.com/publications/rna-sequencing-to-characterize-pathways-in-patients-with-egfr-mutated-non-small-cell-lung-cancer/ 2025-01-31T22:17:11+00:00 https://www.tempus.com/publications/ntrk-expression-is-common-in-xanthogranuloma-and-is-associated-with-the-solitary-variant/ 2025-01-31T22:21:19+00:00 https://www.tempus.com/news/acquisition-of-ambry-genetics/ 2025-02-03T21:48:56+00:00 https://www.tempus.com/resources/content/articles/qa-navigating-the-outcomes-research-landscape/ 2025-02-04T16:33:39+00:00 https://www.tempus.com/wp-content/uploads/2025/01/QA_-Navigating-the-outcomes-research-landscape.png https://www.tempus.com/events/liquid-biopsy-for-precision-oncology-summit-2025/ 2025-02-07T22:41:15+00:00 https://www.tempus.com/news/tempus-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-24/ 2025-02-11T13:30:24+00:00 https://www.tempus.com/resources/content/white-papers/the-future-of-immuno-oncology-research-challenges-innovations-and-the-role-of-data-driven-solutions/ 2025-02-10T17:04:51+00:00 https://www.tempus.com/wp-content/uploads/2024/12/Case-Study_The-future-of-immuno-oncology-research.jpg https://www.tempus.com/publications/efficient-and-generalizable-prediction-of-molecular-alterations-in-multiple-cancer-cohorts-using-hematoxylin-and-eosin-whole-slide-images/ 2025-02-10T17:36:19+00:00 https://www.tempus.com/publications/circulating-tumor-dna-as-a-prognostic-biomarker-for-cdk-4-6-inhibitor-therapy-in-metastatic-breast-cancer/ 2025-02-12T19:09:10+00:00 https://www.tempus.com/publications/a-case-of-sequential-alpelisib-and-capivasertib-in-a-patient-with-metastatic-breast-cancer-harboring-both-a-pik3ca-and-akt-mutations/ 2025-02-12T19:11:35+00:00 https://www.tempus.com/publications/effects-of-socioeconomic-status-on-access-to-next-generation-sequencing-in-patients-with-metastatic-breast-cancer/ 2025-02-12T19:14:50+00:00 https://www.tempus.com/publications/genomic-profiles-of-early-progressors-vs-exceptional-responders-on-cdk4-6i-in-er-her2-advanced-breast-cancer/ 2025-02-12T19:16:55+00:00 https://www.tempus.com/publications/correlation-of-mutational-changes-in-circulating-tumor-dna-with-clinical-outcomes-in-her2-positive-metastatic-breast-cancer/ 2025-02-12T19:18:51+00:00 https://www.tempus.com/publications/multicenter-retrospective-cohort-study-of-the-sequential-use-of-antibody-drug-conjugates-trastuzumab-deruxtecan-sacituzumab-govitecan-in-patients-with-her2-low-metastatic-breast-cancer-a-subgroup-a/ 2025-02-12T19:21:03+00:00 https://www.tempus.com/news/tempus-announces-collaboration-with-ifli-aimed-at-supporting-development-of-targeted-therapies-for-follicular-lymphoma/ 2025-02-13T13:30:33+00:00 https://www.tempus.com/publications/impact-of-psa-nadir-on-long-term-survival-in-metastatic-hormone-sensitive-prostate-cancer-final-10-year-analysis-of-the-ecog-acrin-e3805-chaarted-trial/ 2025-02-13T16:14:59+00:00 https://www.tempus.com/publications/molecular-subtypes-nectin4-her2-expression-and-clinical-outcomes-in-patients-pts-with-advanced-urothelial-carcinoma-auc-or-muscle-invasive-bladder-cancer-mibc-exploratory-analyses-from-javeli/ 2025-02-13T16:18:42+00:00 https://www.tempus.com/resources/content/articles/qa-exploring-the-implications-of-chip-on-oncology-patient-care/ 2025-02-14T18:42:00+00:00 https://www.tempus.com/wp-content/uploads/2025/02/QA_-Exploring-the-implications-of-CHIP-on-oncology-patient-care.png https://www.tempus.com/publications/acquired-rufy1-ret-rearrangement-as-a-mechanism-of-resistance-to-lorlatinib-in-a-patient-with-cd74-ros1-rearranged-non-small-cell-lung-cancer-a-case-report/ 2025-02-15T00:00:38+00:00 https://www.tempus.com/publications/real-world-outcomes-of-alk-fusion-types-and-treatment-patterns-in-alk-positive-nsclc-insights-from-a-retrospective-cohort-study/ 2025-02-17T16:34:06+00:00 https://www.tempus.com/publications/correlation-of-mesothelin-msln-expression-measured-by-rna-sequencing-rnaseq-and-immunohistochemistry-ihc-in-msln-expressing-tumors/ 2025-02-17T16:41:41+00:00 https://www.tempus.com/news/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference/ 2025-02-18T13:30:38+00:00 https://www.tempus.com/news/tempus-to-present-at-td-cowens-45th-annual-health-care-conference/ 2025-02-19T13:30:40+00:00 https://www.tempus.com/news/media-coverage/cnbc-2025/ 2025-02-17T23:45:20+00:00 https://www.tempus.com/resources/content/webinars/ai-ml-in-action-real-time-advances-in-precision-medicine/ 2025-02-19T03:21:01+00:00 https://www.tempus.com/wp-content/uploads/2023/05/Tempus-webinar_nP-PGx.jpg https://www.tempus.com/publications/real-world-clinical-multi-omics-analyses-reveal-bifurcation-of-er-independent-and-er-dependent-drug-resistance-to-cdk4-6-inhibitors/ 2025-02-19T22:57:38+00:00 https://www.tempus.com/resources/content/articles/oncology-innovation-how-emerging-biotechs-lead-through-rwd-and-ai/ 2025-02-20T17:42:46+00:00 https://www.tempus.com/wp-content/uploads/2025/02/Oncology-innovation_-How-emerging-biotechs-lead-through-RWD-AI.png https://www.tempus.com/wp-content/uploads/2023/04/KRAS-Expression_KRAS-Mutation-Status.png https://www.tempus.com/wp-content/uploads/2023/04/KRAS-Expression_KRAS-Mutation-Status.png https://www.tempus.com/wp-content/uploads/2023/04/KRAS-Expression_KRAS-Mutation-Status.png https://www.tempus.com/news/tempus-and-stemline-therapeutics-inc-a-subsidiary-of-the-menarini-group-announce-collaboration-to-implement-tempus-next-an-ai-enabled-care-pathway-intelligence-platform-to-support-patients-with-m/ 2025-02-21T16:33:04+00:00